Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 6/2016

Open Access 01-06-2016 | Original Research Paper

Reduced acute myocardial ischemia–reperfusion injury in IL-6-deficient mice employing a closed-chest model

Authors: Willeke M. C. Jong, Hugo ten Cate, André C. Linnenbank, Onno J. de Boer, Pieter H. Reitsma, Robbert J. de Winter, Coert J. Zuurbier

Published in: Inflammation Research | Issue 6/2016

Login to get access

Abstract

Objective and design

We examined the role of IL-6 in the temporal development of cardiac ischemia–reperfusion injury employing a closed-chest I/R model.

Materials/methods

Infarction, local and systemic inflammation, neutrophil infiltration, coagulation and ST elevation/resolution were compared between wild-type (WT) and IL-6-deficient (IL-6−/−) mice after 1 h ischemia and 0, ½, 3, and 24 h reperfusion.

Results

IL-6 deficiency reduced infarct size at 3 h reperfusion (28.8 ± 4.5 % WT vs 17.6 ± 2.5 % IL-6−/−), which reduction persisted and remained similar at 24 h reperfusion (25.1 ± 3.0 % WT vs 14.6 ± 4.4 % IL-6−/−). Serum Amyloid A was reduced at 24 h reperfusion only (57.5 ± 4.9 WT vs 24.8 ± 5.6 ug/ml IL-6−/− mice). Cardiac cytokines (IL-6, IL-1β and TNFα) peaked at 3 h reperfusion, but IL-1β and TNFα levels were unaffected by IL-6 deficiency. Significant neutrophil influx was only detected at 24 h reperfusion and was similar for WT and IL-6−/−. Tissue factor peaked at 24 h reperfusion, whereas fibrin/fibrinogen peaked at 3 h reperfusion and was completely resolved at 24 h reperfusion; both coagulation factors were unaltered by IL-6 deficiency. Prolonged ST elevation was observed during ischemia that completely resolved for both genotypes at early reperfusion.

Conclusions

The data suggest that, in the absence of major surgical intervention, IL-6 contributes to the development of infarct size in the early phase of reperfusion; this contribution did not depend on neutrophil influx, IL-1β and TNFα, tissue factor and fibrin.
Literature
1.
2.
Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. Am J Physiol. 1995;269(6 Pt 2):H2147–54.PubMed
3.
Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 1999;99(4):546–51.CrossRefPubMed
4.
Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation. 1995;92(7):1866–75.CrossRefPubMed
5.
Empana JP, Jouven X, Canoui-Poitrine F, Luc G, Tafflet M, Haas B, Arveiler D, Ferrieres J, Ruidavets JB, Montaye M, Yarnell J, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol. 2010;30(10):2047–52.CrossRefPubMed
6.
Manten A, de Winter RJ, Minnema MC, ten Cate H, Lijmer JG, Adams R, Peters RJ, van Deventer SJ. Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res. 1998;40(2):389–95.CrossRefPubMed
7.
Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, Podewski E, Schieffer B, Rose-John S, Drexler H. Role of interleukin-6 for left ventricular remodeling and survival after experimental myocardial infarction. Faseb J. 2003;17(14):2118–20.PubMed
8.
Samanta A, Cheng G, Davani A, Girgis M, Chen L, Choksi K, Zhao L, Vincent RJ, Hauptman J, Dawn B. Abstract 15693: Genetic Deletion of Interleukin-6 Attenuates Left Ventricular Dysfunction and Remodeling After a Reperfused Myocardial Infarction. Circulation. 2014;130(Suppl 2):A15693.
9.
Kaminski KA, Kozuch M, Bonda TA, Stepaniuk MM, Waszkiewicz E, Chyczewski L, Musial WJ, Winnicka MM. Effect of interleukin 6 deficiency on the expression of Bcl-2 and Bax in the murine heart. Pharmacol Rep. 2009;61(3):504–13.CrossRefPubMed
10.
Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 2004;64(1):61–71.CrossRefPubMedPubMedCentral
11.
McGinnis GR, Ballmann C, Peters B, Nanayakkara G, Roberts M, Amin R, Quindry JC. Interleukin-6 mediates exercise preconditioning against myocardial ischemia reperfusion injury. Am J Physiol Heart Circ Physiol. 2015;308(11):H1423–33.CrossRefPubMed
12.
Nossuli TO, Lakshminarayanan V, Baumgarten G, Taffet GE, Ballantyne CM, Michael LH, Entman ML. A chronic mouse model of myocardial ischemia–reperfusion: essential in cytokine studies. Am J Physiol Heart Circ Physiol. 2000;278(4):H1049–55.PubMed
13.
Jong WMC, Leemans JC, Weber NC, Juffermans NP, Schultz MJ, Hollmann MW, Zuurbier CJ. Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression. Int J Cardiol. 2014;177(1):41–3.CrossRefPubMed
14.
Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology. 2000;32(1):49–55.CrossRefPubMed
15.
Hawkins HK, Entman ML, Zhu JY, Youker KA, Berens K, Dore M, Smith CW. Acute inflammatory reaction after myocardial ischemic injury and reperfusion. Development and use of a neutrophil-specific antibody. Am J Pathol. 1996;148(6):1957–69.PubMedPubMedCentral
16.
Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996;76(5):738–42.PubMed
17.
van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, Eerenberg AJ, de Groot ER, Jansen J, Gallati H, Buller HR, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994;179(4):1253–9.CrossRefPubMed
18.
Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia–reperfusion injury by reducing inflammation. Am J Pathol. 2000;157(6):1849–62.CrossRefPubMedPubMedCentral
19.
Gehrmann J, Frantz S, Maguire CT, Vargas M, Ducharme A, Wakimoto H, Lee RT, Berul CI. Electrophysiological characterization of murine myocardial ischemia and infarction. Basic Res Cardiol. 2001;96(3):237–50.CrossRefPubMed
20.
Li RA, Leppo M, Miki T, Seino S, Marban E. Molecular basis of electrocardiographic ST-segment elevation. Circ Res. 2000;87(10):837–9.CrossRefPubMed
21.
Jong WMC, Reitsma PH, ten Cate H, de Winter RJ. Modified two-step model for studying the inflammatory response during myocardial ischemia and reperfusion in mice. Comp Med. 2003;53(5):522–6.PubMed
22.
Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368(6469):339–42.CrossRefPubMed
23.
Jong WMC, Zuurbier CJ, De Winter RJ, Van Den Heuvel DAF, Reitsma PH, Ten Cate H, Ince C. Fentanyl fluanisone midazolam Combination Results in More Stable Hemodynamics than Does Urethane a-chloralose and 2,2,2-tribromoethanol in Mice. Contemp Top Lab Anim Sci. 2002;41(3):28–32.PubMed
24.
Zuurbier CJ, Koeman A, Houten SM, Hollmann MW, Florijn WJ. Optimizing anesthetic regimen for surgery in mice through minimization of hemodynamic, metabolic, and inflammatory perturbations. Exp Biol Med (Maywood). 2014;239(6):737–46.CrossRef
25.
Xu Z, Alloush J, Beck E, Weisleder N. A murine model of myocardial ischemia–reperfusion injury through ligation of the left anterior descending artery. Journal of visualized experiments JoVE. 2014; (86).
26.
Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Investig. 1998;101(9):1983–91.CrossRefPubMedPubMedCentral
27.
Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg. 2004;128(2):170–9.CrossRefPubMed
28.
Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia–reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004;109(6):784–9.CrossRefPubMed
29.
Durgan DJ, Pulinilkunnil T, Villegas-Montoya C, Garvey ME, Frangogiannis NG, Michael LH, Chow CW, Dyck JR, Young ME. Short communication: ischemia/reperfusion tolerance is time-of-day-dependent: mediation by the cardiomyocyte circadian clock. Circ Res. 2010;106(3):546–50.CrossRefPubMedPubMedCentral
30.
Fisher SG, Marber MS. An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heart. J Pharmacol Toxicol Methods. 2002;48(3):161–9.CrossRefPubMed
31.
32.
Schulz R. TNFalpha in myocardial ischemia/reperfusion: damage vs. protection. J Mol Cell Cardiol. 2008;45(6):712–4.CrossRefPubMed
33.
Patel NSA, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther. 2005;312(3):1170–8.CrossRefPubMed
34.
Zuurbier CJ, Heinen A, Koeman A, Stuifbergen R, Hakvoort TB, Weber NC, Hollmann MW. Cardioprotective efficacy depends critically on pharmacological dose, duration of ischaemia, health status of animals and choice of anaesthetic regimen: a case study with folic acid. J Transl Med. 2014;12(1):325.CrossRefPubMedPubMedCentral
35.
Gao XM, Liu Y, White D, Su Y, Drew BG, Bruce CR, Kiriazis H, Xu Q, Jennings N, Bobik A, Febbraio MA, Kingwell BA, Bucala R, Fingerle-Rowson G, Dart AM, Morand EF, Du XJ. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia–reperfusion injury: a predominant role of anti-inflammation. J Mol Cell Cardiol. 2011;50(6):991–9.CrossRefPubMed
36.
37.
Ji C, Chen X, Gao C, Jiao L, Wang J, Xu G, Fu H, Guo X, Zhao Y. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J Bioenerg Biomembr. 2011;43(4):367–75.CrossRefPubMed
38.
39.
Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol. 2008;83(5):1174–80.CrossRefPubMed
40.
Kim SC, Ghanem A, Stapel H, Tiemann K, Knuefermann P, Hoeft A, Meyer R, Grohe C, Knowlton AA, Baumgarten G. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol. 2007;7:5.CrossRefPubMedPubMedCentral
41.
Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, Spengler RN, Smith CW, Entman ML. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98(7):699–710.CrossRefPubMed
42.
Entman ML, Youker K, Shoji T, Kukielka G, Shappell SB, Taylor AA, Smith CW. Neutrophil induced oxidative injury of cardiac myocytes. A compartmented system requiring CD11b/CD18-ICAM-1 adherence. J Clin Invest. 1992;90(4):1335–45.CrossRefPubMedPubMedCentral
43.
Youker K, Smith CW, Anderson DC, Miller D, Michael LH, Rossen RD, Entman ML. Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion. J Clin Invest. 1992;89(2):602–9.CrossRefPubMedPubMedCentral
44.
Metzler B, Mair J, Lercher A, Schaber C, Hintringer F, Pachinger O, Xu Q. Mouse model of myocardial remodelling after ischemia: role of intercellular adhesion molecule-1. Cardiovasc Res. 2001;49(2):399–407.CrossRefPubMed
45.
Ikeda U, Ikeda M, Kano S, Shimada K. Neutrophil adherence to rat cardiac myocyte by proinflammatory cytokines. J Cardiovasc Pharmacol. 1994;23(4):647–52.CrossRefPubMed
46.
Garcia-Dorado D, Ruiz-Meana M, Piper HM. Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues. Cardiovasc Res. 2009;83(2):165–8.CrossRefPubMed
47.
Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol. 2015;78:129–41.CrossRefPubMed
48.
Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, Hamulyak K, Ferrell G, Esmon CT, Spronk HM, ten Cate H. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol. 2009;29(7):1087–92.CrossRefPubMed
49.
Loubele ST, Spek CA, Leenders P, van Oerle R, Aberson HL, van der Voort D, Hamulyak K, Petersen LC, Spronk HM, ten Cate H. Active site inhibited factor VIIa attenuates myocardial ischemia/reperfusion injury in mice. J Thromb Haemost. 2009;7(2):290–8.CrossRefPubMed
50.
51.
Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172(8):1913–32.CrossRefPubMedPubMedCentral
Metadata
Title
Reduced acute myocardial ischemia–reperfusion injury in IL-6-deficient mice employing a closed-chest model
Authors
Willeke M. C. Jong
Hugo ten Cate
André C. Linnenbank
Onno J. de Boer
Pieter H. Reitsma
Robbert J. de Winter
Coert J. Zuurbier
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 6/2016
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-016-0931-4

Other articles of this Issue 6/2016

Inflammation Research 6/2016 Go to the issue

Original Research Paper

Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus

Review

Distinct roles of TNF-related apoptosis-inducing ligand (TRAIL) in viral and bacterial infections: from pathogenesis to pathogen clearance

Original Research Paper

Exhaled breath markers of alveolar macrophage activity in sarcoidosis

Original Research Paper

The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria

Original Research Paper

Hypoxia-inducible factor-2α induces expression of type X collagen and matrix metalloproteinases 13 in osteoarthritic meniscal cells

Original Research Paper

The infrapatellar fat pad is affected by injury induced inflammation in the rabbit knee: use of dexamethasone to mitigate damage
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits